
Protagonist Therapeutics (PTGX) Stock Forecast & Price Target
Protagonist Therapeutics (PTGX) Analyst Ratings
Bulls say
Protagonist Therapeutics Inc. is demonstrating encouraging clinical results for its drug candidate, icotrokinra, with significant improvements in clinical response and endoscopic outcomes, notably a 31.7% clinical remission rate at 28 weeks in the 400mg cohort. The company anticipates strong growth potential driven by icotrokinra's efficacy in addressing unmet medical needs, particularly in the milder segment market following Otezla's exit, reinforced by a robust safety profile. Additionally, Protagonist's solid business development track record and the expected momentum in its pipeline leading to key catalysts in 2025 support a favorable long-term outlook for the stock.
Bears say
The financial outlook for Protagonist Therapeutics appears negative due to multiple risk factors inherent in the biopharmaceutical industry, including the potential for unexpected safety concerns during clinical trials, which could hinder product development and approval. Additionally, there is significant concern regarding the strategic decisions of partners to continue developing the drug Icotrokinra due to competitive pressures, alongside increasing regulatory scrutiny and pricing risks in the market. Furthermore, the company faces the prospect of future cash needs that may lead to dilution, adding another layer of financial uncertainty to its operations.
This aggregate rating is based on analysts' research of Protagonist Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Protagonist Therapeutics (PTGX) Analyst Forecast & Price Prediction
Start investing in Protagonist Therapeutics (PTGX)
Order type
Buy in
Order amount
Est. shares
0 shares